LGT Group Foundation Has $17.52 Million Stock Position in Colgate-Palmolive (NYSE:CL)

LGT Group Foundation lessened its holdings in Colgate-Palmolive (NYSE:CL) by 21.4% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 180,524 shares of the company’s stock after selling 49,017 shares during the period. LGT Group Foundation’s holdings in Colgate-Palmolive were worth $17,518,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Norges Bank bought a new stake in Colgate-Palmolive in the 4th quarter worth about $731,843,000. Price T Rowe Associates Inc. MD increased its position in shares of Colgate-Palmolive by 27.8% during the first quarter. Price T Rowe Associates Inc. MD now owns 41,067,130 shares of the company’s stock valued at $3,698,096,000 after acquiring an additional 8,933,912 shares during the last quarter. Swedbank AB bought a new stake in Colgate-Palmolive during the first quarter worth $286,370,000. Acadian Asset Management LLC grew its stake in Colgate-Palmolive by 108.4% in the 2nd quarter. Acadian Asset Management LLC now owns 5,682,280 shares of the company’s stock valued at $551,367,000 after purchasing an additional 2,955,442 shares during the period. Finally, Magellan Asset Management Ltd increased its position in shares of Colgate-Palmolive by 4,162.6% during the 4th quarter. Magellan Asset Management Ltd now owns 2,016,290 shares of the company’s stock valued at $160,718,000 after purchasing an additional 1,968,988 shares during the last quarter. Institutional investors own 80.41% of the company’s stock.

Colgate-Palmolive Trading Down 1.1 %

Colgate-Palmolive stock traded down $1.23 during trading hours on Monday, reaching $106.63. The stock had a trading volume of 772,489 shares, compared to its average volume of 4,306,362. The company has a debt-to-equity ratio of 16.90, a current ratio of 1.06 and a quick ratio of 0.70. Colgate-Palmolive has a 52 week low of $67.62 and a 52 week high of $109.30. The stock has a market cap of $87.13 billion, a PE ratio of 34.13, a PEG ratio of 3.78 and a beta of 0.40. The company has a fifty day simple moving average of $101.07 and a 200-day simple moving average of $94.58.

Colgate-Palmolive (NYSE:CL) last posted its earnings results on Friday, July 26th. The company reported $0.91 EPS for the quarter, topping the consensus estimate of $0.87 by $0.04. Colgate-Palmolive had a net margin of 14.21% and a return on equity of 470.19%. The firm had revenue of $5.06 billion during the quarter, compared to analysts’ expectations of $5 billion. During the same period last year, the company posted $0.77 EPS. The company’s quarterly revenue was up 4.9% compared to the same quarter last year. Analysts forecast that Colgate-Palmolive will post 3.57 EPS for the current fiscal year.

Colgate-Palmolive Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, August 15th. Stockholders of record on Friday, July 19th were paid a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.88%. The ex-dividend date of this dividend was Friday, July 19th. Colgate-Palmolive’s payout ratio is presently 63.29%.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on CL. Citigroup increased their price target on shares of Colgate-Palmolive from $103.00 to $112.00 and gave the company a “buy” rating in a research report on Wednesday, July 10th. Jefferies Financial Group lowered Colgate-Palmolive from a “buy” rating to a “hold” rating and reduced their price objective for the company from $103.00 to $95.00 in a report on Wednesday, July 24th. BNP Paribas began coverage on Colgate-Palmolive in a research note on Monday, June 24th. They issued an “outperform” rating and a $109.00 price objective on the stock. Argus increased their target price on shares of Colgate-Palmolive from $97.00 to $107.00 and gave the stock a “buy” rating in a research report on Wednesday, May 15th. Finally, Sanford C. Bernstein upped their price target on shares of Colgate-Palmolive from $100.00 to $103.00 and gave the company a “market perform” rating in a research note on Tuesday, July 30th. Nine equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. Based on data from MarketBeat.com, Colgate-Palmolive has an average rating of “Moderate Buy” and a consensus price target of $102.63.

Insiders Place Their Bets

In other Colgate-Palmolive news, insider Sally Massey sold 15,850 shares of the business’s stock in a transaction on Tuesday, August 6th. The stock was sold at an average price of $103.28, for a total value of $1,636,988.00. Following the sale, the insider now directly owns 13,942 shares of the company’s stock, valued at $1,439,929.76. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, Director Martina Hundmejean sold 2,313 shares of the company’s stock in a transaction that occurred on Friday, August 23rd. The stock was sold at an average price of $103.86, for a total value of $240,228.18. Following the transaction, the director now directly owns 11,755 shares of the company’s stock, valued at approximately $1,220,874.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Sally Massey sold 15,850 shares of the business’s stock in a transaction on Tuesday, August 6th. The stock was sold at an average price of $103.28, for a total value of $1,636,988.00. Following the completion of the transaction, the insider now owns 13,942 shares of the company’s stock, valued at approximately $1,439,929.76. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 43,490 shares of company stock worth $4,486,063. 0.34% of the stock is owned by corporate insiders.

About Colgate-Palmolive

Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products in the United States and internationally. It operates through two segments: Oral, Personal and Home Care; and Pet Nutrition. The Oral, Personal and Home Care segment offers toothpaste, toothbrushes, mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin health products, dishwashing detergents, fabric conditioners, household cleaners, and other related items.